Timing of adjuvant chemotherapy initiation after surgery for stage III colon cancer

Cancer

Volumn 107, Issue 11, 2006, Pages 2581-2588

  Hershman, Dawn ^a,b,c   Hall, Michael J ^a,b   Wang, Xiaoyan ^a   Jacobson, Judith S ^a,b   McBride, Russell ^a   Grann, Victor R ^a,b   Neugut, Alfred I ^a,b  

^a Columbia University ^*  (United States)

^b Columbia University Medical Center ^*  (United States)

^c NewYork Presbyterian Hospital   (United States)

Author keywords

Chemotherapy; Colon cancer; Delay; Elderly; End Results Medicare; Epidemiology; Surveillance

Indexed keywords

FLUOROURACIL;

AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORTALITY; CANCER SURVIVAL; COLON CANCER; COMORBIDITY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; THERAPY DELAY; TREATMENT PLANNING;

AGE FACTORS; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; HUMANS; LYMPHATIC METASTASIS; MEDICARE; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; SEER PROGRAM; SURVIVAL RATE;

EID: 33751581368     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22316     Document Type: Article

References (40)

1. [No authors listed] Polychemotherapy for early breast cancer: an overview of the randomised trials.Early Breast Cancer Trialists' Collaborative Group. Lancet. 1998;352:930-942.
2. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much [see comment]? J Clin Oncol. 2004;22:1797-1806.
3. Hershman D, McBride H, Jacobson JS, et al. Racial disparities in treatment and survival among women with early-stage breast cancer. J Clin Oncol. 2005;23:6639-6646.
4. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003;21:4524-4531.
5. Partridge AH, Wang PS, Winer EP, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602-606.
6. Bickell NA, McEvoy MD. Physicians' reasons for failing to deliver effective breast cancer care: a framework for underuse. Med Care. 2003;41:442-446.
7. Silliman RA, Guadagnoli E, Weitberg AB, et al. Age as a predictor of diagnostic and initial treatment intensity in newly diagnosed breast cancer patients. J Gerontol. 1989;44:M46-M50.
8. Hershman DL, Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay in initiating adjuvant radiotherapy following breast conservation surgery and its impact on survival. Int J Radiat Oncol Biol Phys. 2006;65:1353-1360.
9. Hershman DL Wang X, McBride R, Jacobson JS, Grann VR, Neugut AI. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women. Breast Cancer Res Treat. 2006;99:313-321.
10. Neugut AI, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study [see comment]. J Clin Oncol. 2002;20:2643-2650.
11. Schrag D, Rifas-Shiman S, Saltz L, et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol. 2002;20:3999-4005.
12. Baldwin LM, Dobie SA, Billingsley K, et al. Explaining black-white differences in receipt of recommended colon cancer treatment. J Natl Cancer Inst 2005;97:1211-1220.
13. Sundararajan V, Grann VR, Jacobson JS, et al. Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: a population-based study. Cancer J. 2001;7:213-218.
14. Neugut AI, Matsar M, Wang X, McBride R, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol. 2006;24:2368-2375.
15. Dobie SA, Baldwin LM, Dominitz JA, et al. Completion of therapy by Medicare patients with stage III colon cancer. [see comment]. J Natl Cancer Inst. 2006;98:610-619.
16. Rulyak SJ, Mandelson MT, Brentnall TA, et al. Clinical and sociodemographic factors associated with colon surveillance among patients with a history of colorectal cancer. Gastrointest Endosc. 2004;59:239-247.
17. Rolnick S, Hensley Alford S, Kucera GP, et al. Racial and age differences in colon examination surveillance following a diagnosis of colorectal cancer. J Natl Cancer Inst Monogr. 2005;(35):96-101.
18. Holliday HW, Hardcastle JD. Delay in diagnosis and treatment of symptomatic colorectal cancer. Lancet. 1979;1:309-311.
19. Langenbach MR, Schmidt J, Neumann J, et al. Delay in treatment of colorectal cancer: multifactorial problem. World J Surg. 2003;27:304-308.
20. Caplan LS. Disparities in breast cancer screening: is it ethical? Public Health Rev. 1997;25:31-41.
21. Caplan LS, Wells BL, Haynes S. Breast cancer screening among older racial/ethnic minorities and whites: barriers to early detection. J Gerontol. 1992;47(spec no):101-110.
22. Wolmark N, Rockette H, Wickerham DL, et al. Adjuvant therapy of Dukes' A, B, and C adenocarcinonia of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project protocol C-02. J Clin Oncol. 1990;8:1466-1475.
23. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol. 1993;11:1879-1887.
24. Wolmark N, Bryant J, Smith R, et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J Natl Cancer Inst. 1998;90:1810-1816.
25. Potosky AL, Riley GF, Lubitz JD, et al. Potential for cancer related health services research using a linked Medicare-tumor registry database. Med Care. 1993;31:732-748.
26. Klabunde CN, Potosky AL, Legler IM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-1267.
27. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40:IV-55-IV-61.
28. Bach PB, Cramer LD, Warren JL, et al. Racial differences in the treatment of early-stage lung cancer [see comment]. N Engl J Med. 1999;341:1198-1205.
29. Charlson ME, Sax FL, MacKenzie CR, et al. Assessing illness severity: does clinical judgment work? J Chron Dis. 1986;39:439-452.
30. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
31. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: an overview. Med Care. 2002;40:IV-26-IV-35.
32. Poplin EA, Benedetti JK, Estes NC, et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol. 2005;23:1819-1825.
33. Polite BN, Dignam JJ, Olopade OI. Colorectal cancer and race: understanding the differences in outcomes between African Americans and whites. Med Clin North Am. 2005;89:771-793.
34. Schrag D, Cramer LD, Bach PB, et al. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J the Natl Cancer Inst. 2001;93:850-857.
35. Colleoni M, Price K, Castiglione-Gertsch M, et al. Doseresponse effect of adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) in node-positive breast cancer. International Breast Cancer Study Group. Eur J Cancer. 1998;34:1693-1700.
36. Shannon C, Ashley S, Smith IE. Does timing of adjuvant chemotherapy for early breast cancer influence survival? J Clin Oncol. 2003;21:3792-3797.
37. Cold S, During M, Ewertz M. et al. Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer?. Results of the Danish Breast Cancer Cooperative Group (DBCG). Br J Cancer. 2005;93:627-632.
38. Malin JL, Schneider EC, Epstein AM, et al. Results of the National Initiative for Cancer Care Quality: how can we improve the quality of cancer care in the United States? J Clin Oncol. 2006;24:626-634.
39. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000;35:181-200.
40. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-1587.